Pay in 4 interest-free payments of $5.31 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Both face the same 2027-2028 approval timeline
These models help researchers explore how localized biological systems maintain communication and regulatory balance under experimental conditions
On NAD+, the brand offers three delivery formats, each with a different brand-stated tradeoff: Injection: what the brand calls the highest bioavailability Oral liquid drops: positioned for at-home convenience Nasal spray: a middle ground the brand associates with potential cognitive benefits The brand states that "many patients report" energy improvements and mental clarity within the first week of injectable NAD+ - again, a brand-reported patient experience, not an independently audited result
AOD-9604 has not been approved by the FDA or any major regulatory body for human therapeutic use
